Ranitidin-Cophar
Category
Ranitidin-Cophar Brand names, Ranitidin-Cophar Analogs
Ranitidin-Cophar Brand Names Mixture
Tritec (ranitidine bismuth citrate salt)
Ranitidin-Cophar Chemical_Formula
C13H22N4O3S
Ranitidin-Cophar RX_link
http://www.rxlist.com/cgi/generic2/ranitbc.htm
Ranitidin-Cophar fda sheet
Ranitidin-Cophar msds (material safety sheet)
Ranitidin-Cophar Synthesis Reference
B. J. Price et al., U.S. Pat. 4,128,658 (1978)
Ranitidin-Cophar Molecular Weight
314.405 g/mol
Ranitidin-Cophar Melting Point
69-70 oC
Ranitidin-Cophar H2O Solubility
24.7 mg/mL
Ranitidin-Cophar State
Solid
Ranitidin-Cophar LogP
1.93
Ranitidin-Cophar Dosage Forms
Capsule; Liquid; Solution; Tablet; Syrup
Ranitidin-Cophar Indication
Used in the treatment of peptic ulcer disease (PUD), dyspepsia, stress ulcer prophylaxis, and gastroesophageal reflux disease (GERD).
Ranitidin-Cophar Pharmacology
Ranitidine is a histamine H2-receptor antagonist similar to cimetidine and famotidine. An H2-receptor antagonist, often shortened to H2 antagonist, is a drug used to block the action of histamine on parietal cells in the stomach, decreasing acid production by these cells. These drugs are used in the treatment of dyspepsia, however their use has waned since the advent of the more effective proton pump inhibitors. Like the H1-antihistamines, the H2 antagonists are inverse agonists rather than true receptor antagonists.
Ranitidin-Cophar Absorption
Approximately 50% bioavailability orally.
Ranitidin-Cophar Toxicity
LD50=77mg/kg (orally in mice). Symptoms of overdose include muscular tremors, vomiting, and rapid respiration.
Ranitidin-Cophar Patient Information
PATIENT INFORMATION
Phenylketonurics: ZANTAC 25 EFFERdose Tablets contain phenylalanine 2.81 mg per 25 mg of ranitidine. ZANTAC 150 EFFERdose Tablets
contain phenylalanine 16.84 mg per 150 mg of ranitidine. ZANTAC EFFERdose Tablets should not be chewed, swallowed whole, or dissolved
on the tongue.
Ranitidin-Cophar Organisms Affected
Humans and other mammals
